AⅡ受体拮抗剂ACEI对慢性肾衰患者血浆ANF及RAS的影响

目的了解血管紧张素Ⅱ受体拮抗剂(ATRA)和转换酶抑制剂(ACEI)对慢性肾衰(CRF)高血压患者血浆心钠素(ANF)和肾素*.血管紧张素系统(RAS)的影响。方法受试者口服氯沙坦(Los组)或福辛普利(Fos组)连续12周，于治疗前和治疗后第4、8及12周测定坐位舒张压(SiDBP)、血清尿素氮(BUN)、血清肌酐(SCr)、ANF、血管紧张素Ⅰ(AⅠ)和血管紧张素Ⅱ(AⅡ)。用SPSS7.0软件作统计分析。结果经12周治疗，两组患者SiDBP均降至目标值。Fos组与治疗前比较，AⅡ下降，ANF和Scr升高(P<0.01)。Los组AⅡ明显升高(P<0.01)，ANF在短暂升高后降至治疗前水平，Scr无变化。结论ACEI可能对CRF高血压患者肾内灌注压有影响，ANF动态改变可作为肾内灌注压变化的指标之一。ATRA对肾内灌注压影响小于ACEI。     

带蚓状肌的游离足趾再造拇、手指

自１９７２年以来，在游离足趾再造拇、手指手术中，应用足趾蚓状肌与缺损拇、手指蚓状肌残端或关节囊进行缝合的方法共完成手术３００例，由于再造拇、手指的蚓状肌得到修复，既改善了其指间关节屈曲畸形，又防止了掌指关节的过伸。术后随访１－２２年，再造拇、手指的外形及功能均满意。     

人外周血CD68^＋单核细胞体外的分选及诱导分化为破骨细胞

OBJECTIVE: To establish a method for obtaining highly purified primary human osteoclast precursors for the biochemical and molecular biological research. METHODS: CD68(+) mono/macrophages were separated from peripheral blood mononuclear cells (PBMCs) of healthy donors by means of immunomagnetic cell sorting for subsequent analysis with flow cytometry. The isolated cells were incubated on coverslips or bone slices in the presence of dexamethasone(10(-8) mol/L), macrophage colony-stimulating factor (25 microg/L ) and soluble receptor activator of nuclear factor (NF)-kappaB ligand (s-RANKL, 16 microg/L). Calcitonin receptor (CR) immunocytochemistry and tartrate-resistant acid phosphatase (TRAP) histochemistry were employed. The bone slices were also studied by scanning electron microscopy (SEM). RESULTS: Fluorescence-activated cytometric analysis showed that 93.06%+/-0.61% n=4 of the selected cells were CD68(+) cells. After 7 days of culture of the CD68(+) cells, VR+, TRAP+ multinucleated giant cells appeared, and resorption lacunae could be observed by SEM. CONCLUSION: Highly purified CD68(+) cells can be obtained from human PBMCs as the osteoclast precursors, and mature osteoclasts can be induced from CD68(+) mono/macrophages by RANKL.     

太太,十年打造金字招牌

一个企业风光几年,在全世界都是一种普遍现象。在日本曾经做过统计,经营历史超过5年的企业不到20%,80%都在5年内消失了。然而创建于1992年12月18日的深圳太太药业股份有限公司,虽然是以保健品起家,多年来却一直保持着持续稳定的增长势头,成为行业的翘楚。1993年3月8日面市以来,太太口服液已连续畅销近十年,静心口服液上市三年来,销售也一直保持快速的增长态势,在2001年度销售更是势头迅猛,年销售额达21,656.62万元;同时,在OTC药品方面,太太药业陆续推出了意可贴、正源丹、汉林清脂等一系列产品,市场反应都极为积极,2000年推出的意可贴,更是用小药做出了大市场,赢得了非常理想的市场份额和患者口碑。2001年6月8日,深圳太太药业股份有限公司在上海证交所挂牌上市,并一举融资17亿,2002年4月3日太太药业股份有限公司发布公告,拟变更募集资金用途,用于收购健康药业“中国”有限公司100%股权及购买鹰牌商标物注册商标所有权。此次受让健康药业股权及鹰牌商标款共计折台人民币14,151万元。这是太太药业上市面上后首次的收购行动,也是资本在太太药业身上的首次说话。太太,已经变得越来越强大,用太太药业董事长朱保国的话说:低于10亿美元,别想买太太药业。那么,太太是如何取得今天的成就的呢?     

外伤性肝破裂的救治

目的 分析创伤性肝破裂外科多种干预治疗的效果。方法 总结分析1982-2002年我院收治创伤性肝破裂76例的救治方法和病死率。其中Ⅲ级以上的严重肝破裂46例(60．53％)。手术治疗56例，手术方式包括单纯修补、清创性肝切除、规则性肝切除、肝周填塞止血；非手术治疗20例。结果 手术组：治愈44例，术后并发症17例均经保守治疗治愈，死亡12例，其中术中死亡2例；非手术组：治愈12例，好转6例，2例失访。全组治愈64例，死亡12例，病死率15．8％。结论 Ⅰ-Ⅱ级单纯性外伤性肝破裂可保守治疗；手术是治疗创伤性肝破裂的主要措施，正确的手术方式，积极处理合并伤，重视综合治疗可提高救治成功率。     

老年人肱骨近端二部分和三部分移位骨折19例临床分析

目的 探讨老年人肱骨近端二部分和三部分移位骨折的手术治疗方法。方法 回顾性分析19例老年肱骨近端二部分和三部分移位骨折患者的临床资料，其中二部分骨折13例、三部分骨折6例，采用切开复位，肱骨近端解剖钢板固定治疗。结果 二部分骨折术后优良率为76．9％，未出现骨折不愈合及肱骨头坏死；三部分骨折术后优良率为66．7％，肱骨头坏死率16．7％。结论 老年人肱骨近端二部分和三部分骨折应尽量采用有限切开复位，选择肱骨近端解剖钢板固定。     

磨损微粒诱导的局部生物学反应

人工髋关节置换失败的主要原因是假体的无菌性松动。研究表明 ,这和假体长期磨损产生的微粒作用于周围的巨噬细胞而诱发的生物学反应有关。磨损微粒激活假体周围组织细胞释放前炎症介质 ,诱导破骨细胞的活化和分化 ,引发假体周围的骨溶解。充分地认识这个过程 ,对减少人工关节无菌性松动 ,延长假体使用寿命具有重要意义。     

大黄(庶虫)虫丸治疗囊肿性痤疮的临床疗效评价

目的　观察大黄虫丸治疗囊肿性痤疮的临床疗效。　方法　选择囊肿性痤疮患者 33 例做为治疗组,给予口服大黄虫丸治疗,观察并记录结果。　结果　治疗的总有效率为 90 9%,对照组(P<0 05)。　结论　大黄虫丸对囊肿性痤疮有较好的临床疗效。     

Inhibitory Effect of Angiogenesis Inhibitor TNP—470 on Human ACHN Renal Cell Carcinoma

Angiogenesis,the formation of new bloodvessels,is necessary for the growth of tumors andtheir metastasis.TNP- 470 is a synthetic analogueof fumagillin and has stronger antiangiogenic　 ac-tivity and less side- effects than fumagillin.Thiscompound has been reported to suppress the prolif-eration and metastasis of various kinds of tu-mors[1] . Using nude mice xenografts of ACHN hu-man renal cell carcinoma ( RCC) ,the presentstudyattempted to examine the action of TNP- 470 ongrowth,metastasi…     

Immunogenicity study of low-dose administration of hepatitis B virus vaccine in newborn infants: A cost reduction trial

Different doses of hepatitis B virus vaccine—prepared by Korea Green Cross Corporation, were given to healthy infants born to HBsAg-negative mothers at birth, 1 and 6 months of age. A dose of 2 μg was administered intradermally in Group A and, in the three other groups, the vaccine was given intramuscularly (i.m.). An adequate follow-up observation was possible for 9 months after birth in 22, 25, 23 and 21 infants in Groups A, B, C and D, respecvely.
Group C (5 μg, i.m.) produced seroconversion most rapidly, showing the highest rate (96%) at 9 months of age. The lowest seroconversion rate (5%) was found at the age of 1 month in Group A subjects, but the rate increased to 91% after a booster dose was given at 6 months of age.
While it can be concluded that a 5 μg i.m. dose of vaccine at 0, 1 and 6 months of age is optimum for the immunization of infants in efficacy and economy, a 2 μg intradermal dose can also be considered as an immunogenic and economical regimen, though the immune response is slower and a special technique is required for immunization.